Abbott said Kevin Conroy was named to its Board of Directors on April 24, 2026, and on the same day the Board amended its by-laws to provide that the Board shall consist of thirteen persons. The by-laws previously provided that the Board consisted of twelve persons.

1. 01

   Abbott said Kevin Conroy was named to its Board of Directors on April 24, 2026, and on the same day the Board amended its by-laws to provide that the Board shall consist of thirteen persons. The by-laws previously provided that the Board consisted of twelve persons.

2. 02

   Abbott said the Abbott Laboratories 2026 Incentive Stock Program was approved at the shareholders meeting on April 24, 2026 with 95.82% of votes cast in favor. The program was adopted by the Board on February 20, 2026, replaces the 2017 Program, and has a term of ten years.

3. 03

   Abbott said the maximum number of Abbott common shares that may be issued under the 2026 Program is 140,000,000, plus shares that cease to be subject to awards under the 2017 Program due to forfeiture, expiration, cancellation, or cash settlement, and less shares subject to awards granted under the 2017 Program between March 1, 2026 and April 23.

4. 04

   Abbott said the advisory vote on the compensation of its named executive officers was approved at the shareholders meeting on April 24, 2026 with 90.35% of votes cast in favor, and the appointment of Ernst & Young LLP as auditors was approved with 1,502,083,607 shares cast in favor.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.